1. Ceftazidime Poloxamer Gel: Expanding the Therapeutic Armamentarium for Ciprofloxacin-Resistant Pseudomonas Mastoid Cavity Otorrhea.
- Author
-
Roy CF, Cohen-Tenoudji B, and Mijovic T
- Subjects
- Humans, Female, Male, Middle Aged, Retrospective Studies, Mastoid surgery, Drug Resistance, Bacterial, Otitis Media with Effusion drug therapy, Otitis Media with Effusion microbiology, Otitis Media with Effusion surgery, Aged, Adult, Administration, Topical, Ciprofloxacin therapeutic use, Ciprofloxacin administration & dosage, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents administration & dosage, Pseudomonas Infections drug therapy, Pseudomonas Infections microbiology, Ceftazidime therapeutic use, Ceftazidime administration & dosage, Poloxamer, Gels
- Abstract
Objective: To present and evaluate the treatment of ciprofloxacin-resistant Pseudomonas mastoid cavity otorrhea with a ceftazidime thermosensitive poloxamer gel., Study Design: A retrospective clinical capsule report., Patients: Three patients diagnosed with ciprofloxacin-resistant Pseudomonas otorrhea in the setting of a previous canal-wall-down mastoidectomy between March 2019 and June 2023 visiting our tertiary care institution were retrospectively reviewed., Intervention: Application of a 2% ceftazidime thermosensitive poloxamer gel to mastoid cavity., Main Outcome Measures: No evidence of disease during microscopic inspection of the ear within a month of initial treatment or bacterial eradication on subsequent culture., Results: Two patients had complete resolution of symptoms and achieved a safe and dry ear after topical application of the hydrogel. The second patient had pseudomonal eradication on culture, but persistent otorrhea due to other multidrug-resistant bacteria and an anatomically unfavorable mastoid cavity, which ultimately resolved after revision surgery., Conclusions: This small case series suggests that topical treatment of mastoid cavity otorrhea with a 2% ceftazidime poloxomer gel is a potential therapeutic avenue in patients with ciprofloxacin-resistant Pseudomonas ., Competing Interests: The authors disclose no conflicts of interest., (Copyright © 2024, Otology & Neurotology, Inc.)
- Published
- 2024
- Full Text
- View/download PDF